By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



99 Hayden Avenue
Suite 390
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-357-2333 Fax: 781-357-2399



Company News
Pulmatrix Reports Third Quarter 2016 Financial Results And Business Update 11/4/2016 10:29:11 AM
Pulmatrix Will Present Promising New Data At The North American Cystic Fibrosis Conference On October 27-29, 2016 10/11/2016 10:53:57 AM
Dr. Matthew L. Sherman Joins Pulmatrix's Board Of Directors 10/3/2016 9:47:05 AM
Pulmatrix Highlights Recent Report Predicting Rapid Growth For Inhaled Drug Delivery Methods 9/23/2016 9:59:10 AM
Pulmatrix Will Discuss Progress At The Aegis Growth Conference On September 21, 2016 9/7/2016 11:12:29 AM
Pulmatrix To Present At The Rodman & Renshaw Global Investment Conference On September 12, 2016 8/31/2016 11:26:50 AM
Pulmatrix Receives Orphan Drug Designation From The FDA For Inhaled Drug To Treat Pulmonary Fungal Infections In Cystic Fibrosis Patients 8/18/2016 6:51:34 AM
Pulmatrix Reports Q2 2016 Financial Results 8/4/2016 9:55:32 AM
Pulmatrix And Mylan (MYL) Report Positive Pharmacokinetic Bioavailability Data In Pilot Study Of PUR0200 In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/19/2016 6:52:41 AM
Pulmatrix's iSPERSE Focus Of Interview With News Medical 7/6/2016 8:33:57 AM